I once actually committed an act of journalism. I interviewed Hall of Fame relief pitcher Rich Gossage. It took place in January 2010 and it was a fantastic experience. Gossage was polite, accommodating, expansive and interesting. Most of all, his answers seemed very thoughtful. He wasn’t spouting off talking points or cliches. He was thinking about his answers and explaining himself.
The topic: mostly PED users and the Hall of Fame. Like most former players, Gossage was unhappy with the scourge of steroids. But he also struck a very realistic tone at the time, noting how complicated the matter was. His money quote, given in response to what he and other Hall of Famers might do if/when it is discovered that a current member of the Hall of Fame used PEDs, was this:
“I don’t really know what I’d do. We’d have to find out all the facts. It’s a big dark cloud. I don’t know what the scenario would look like“
He added that how the Hall of Fame voters treated guys like Barry Bonds and Roger Clemens, saying “if they let in some of those guys, I guess things are different. What I said about integrity yesterday still stands, but as for the Hall, we’d have to see how the writers handled it. I can only speak for what I believe.” He concluded by saying that he had no problem with cocaine users such as Dave Parker or Tim Raines being inducted.”
In the past four years Gossage’s tone on the matter has shifted from one of personal disapproval — here’s what I believe, but it’s not all up to me, as it were — to one far greater certainty and stridence. He spoke to the New York Post over the weekend, slamming PED users and arguing that all of the pre-PED home run records should be restored. He said “are you f***ing kidding me?” regarding PED guys and then offered a lot of nonsense about Ken Griffey Jr. and great home run hitters’ aging patterns (note: Hank Aaron, like Bonds, had some of his best seasons late in his career).
I don’t know what has changed with Gossage over the past four years to change him from a guy who, while believing what he believed about PEDs, did not believe he had a monopoly on wisdom on the matter to a guy who is so damn certain and, if you put him in charge, would purge records from the books. But given my previous interaction with him, it’s somewhat disappointing.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.